

LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for Mixed Lineage Leukemia-Rearranged acute leukemia

Gabriel Gracia-Maldonado, Jason Clark, Matthew Burwinkel, Brenay Greenslade, Mark Wunderlich, Nathan Salomonis, Dario Leone, Evelina Gatti, Philippe Pierre, Ashish Kumar, et al.

▶ To cite this version:

Gabriel Gracia-Maldonado, Jason Clark, Matthew Burwinkel, Brenay Greenslade, Mark Wunderlich, et al.. LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for Mixed Lineage Leukemia-Rearranged acute leukemia. Haematologica, 2020, 10.3324/haematol.2020.257451. hal-03385563

HAL Id: hal-03385563 https://amu.hal.science/hal-03385563

Submitted on 19 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1

2 LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy

3 target in MLL-r leukemia

- 4 Gabriel Gracia-Maldonado^{1, 2, 3}, Jason Clark^{2, 3}, Matthew Burwinkel^{3,5}, Mark
- 5 Wunderlich^{2,5}, Dario Leone⁴, Philippe Pierre⁴, Evelina Gatti⁴, Lynn H. Lee^{2, 7}, Ashish R.
- 6 Kumar^{2, 3, 6}

7 Affiliations

- ⁸ ¹Pathobiology and Molecular Medicine Graduate Program, University of Cincinnati
- 9 School of Medicine, Cincinnati, OH, 45267, USA.
- ¹⁰ ²Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center,
- 11 Cincinnati, OH, 45229, USA
- ¹² ³Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati,
- 13 Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
- ¹⁴ ⁴Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France.
- ¹⁵ ⁵Division of Experimental Hematology and Cancer Biology, Cincinnati, Children's
- 16 Hospital Medical Center, Cincinnati, OH, 45229, USA
- ⁶Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH,
 45229, USA.
- ⁷Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,
 45229, USA.
- 21 **Running Title:** The LAMP5 as a essential target of MLL-r leukemias

22 Keywords: Leukemia; MLL; LAMP5; innate Immunity

23 **Conflict of Interest:** The authors have declared that no conflict of interest exists.

24 Corresponding Author:

- 25 Ashish R. Kumar
- 26 Cincinnati Children's Hospital Medical Center
- 27 3333 Burnet Avenue, MLC 11027
- 28 Cincinnati, OH 45229
- 29 Phone#: (513) 803-2994
- 30 Email: <u>Ashish.Kumar@cchmc.org</u>

31 Abstract:

Although great advances have been made in understanding the pathobiology of MLL-32 rearranged (MLL-r) leukemias, effective therapies for this leukemia have remained 33 limited, and clinical outcomes remain bleak. To identify novel targets for immunotherapy 34 treatments, we compiled a lineage-independent MLL-r leukemia gene signature using 35 publicly available data sets. Data from large leukemia repositories were filtered through 36 37 the In-silico Human Surfaceome, providing a list of highly predicted cell surface proteins over-expressed in MLL-r leukemias. LAMP5, a lysosomal associated membrane protein, 38 is expressed highly and specifically in MLL-r leukemia. We found that LAMP5 is a direct 39 40 target of the oncogenic MLL-fusion protein (MLL-FP). LAMP5 depletion significantly inhibited leukemia cell growth in vitro and in vivo. Functional studies showed that LAMP-41 5 is a novel modulator of innate-immune pathways in MLL-r leukemias. Downregulation 42 of LAMP5 led to inhibition of NF-kB signaling and increased activation of type-1 interferon 43 (IFN-1) signaling downstream of TLR/IL1R activation. These effects were attributable to 44 the critical role of LAMP5 in transferring the signal flux from Interferon Signaling 45 Endosomes (IRF-SE) to Pro-Inflammatory Signaling Endosome (PI-SE). Depletion of 46 Interferon Response Factor 7 (IRF7) was able to partially rescue the cell growth inhibition 47 48 upon LAMP5 downregulation. Lastly, LAMP-5 was readily detected on the surface of MLLr leukemia cells. Targeting surface LAMP-5 using an antibody drug conjugate lead to 49 significant cell viability decrease specifically on MLL-r leukemias. Overall, based on our 50 51 results and the limited expression throughout human tissues, we postulate that LAMP-5 52 could potentially serve as an immunotherapeutic target with a wide therapeutic window to treat MLL-r leukemias. 53

54 Introduction

Translocations in the Mixed Lineage Leukemia (MLL) gene account for 10% of all human 55 leukemias and are associated with pediatric, adult, and therapy-related cases(1–3). In 56 infants, around 80% of acute lymphoid leukemia (ALL) and 35%-50% of acute myeloid 57 leukemia (AML) cases carry a translocation in the MLL gene (4–6). However, despite 58 improvements in conventional chemotherapies treatments for leukemia, patients with 59 60 MLL-rearranged leukemia (MLL-r) have poor response to treatment and poor prognosis (7, 8). Immunotherapy strategies have proven effective in multiple blood cancers, mainly 61 targeting lineage specific proteins like CD19 (blinatumomab, tisagenlecleucel) and CD33 62 63 (gemtuzumab), abundantly expressed in Acute Lymphoid Leukemia (ALL) and Acute Myeloid Leukemia (AML) patients respectively(9). However, mounting evidence in recent 64 clinical trials and case reports have shown that patients with MLL-rearrangements 65 frequently relapse after treatment with CD19 immunotherapies, arising as AML or Mixed 66 Phenotype Acute Leukemia (MPAL) (10–18). The exact mechanism of linage switch 67 remains unclear, although several possible mechanisms have been proposed(11, 15, 18-68 22). 69

One approach to overcome this immune escape is to develop MLL-r specific immunotherapies targeting cell surface proteins essential for the survival of MLL-r leukemias. Gene-expression profiling based on underlying cytogenetic mutations is one way to identify proteins that are over-expressed and thus might be essential for the propagation of the specific leukemia(30–32). Both AMLs and ALLs with MLLrearrangements share a common gene signature that is distinct from that of MLL-Germline (MLL-Germ) leukemias(33–35). Most of the well studied and validated MLL-r

gene targets however are DNA binding proteins like the HOXA gene cluster and its cofactor MEIS1(36–43), which are not suitable targets for immunotherapy.

Advances in labeling and mass spectrometry have provided new strategies to more 79 accurately identify cell surface proteins in cancer(23). However, the focus has been on 80 finding suitable targets for acute leukemias without distinguinshing between underlying 81 cytogenetic mutations(24–27). The recently published in-silico human surfaceome 82 83 provides a highly accurate surface protein dataset based on the experimental evidence from 41 human tissues within the Cell Surface Protein Atlas. This tool allows for further 84 characterization of proteins-of-interest, specifically surface-expression (28, 29). In several 85 86 of the published gene-expression studies, we found *LAMP5* significantly and specifically over-expressed in MLL-r leukemias(34, 35, 44-46). LAMP-5 is a member of the 87 Lysosome-Associated Membrane Protein (LAMP) family. In contrast to other LAMPs, 88 which show widespread expression, LAMP5 expression in mice is confined to several 89 regions of the postnatal brain. In neurons, the protein was found to recycle between the 90 plasma membrane and a non-classical endosomal vesicle (47-49). In humans, aside 91 from its conserved expression in the brain, LAMP5 is specifically expressed in 92 93 plasmacytoid dendritic cells (pDCs)(50, 51). Upon activation of pDCs, LAMP-5 aids in the 94 transport of Toll-Like Receptor 9 (TLR9) from early endosomal to lysosomal signaling vesicles, thereby regulating type 1 Interferon (IFN-1) and pro-inflammatory signaling 95 respectively, downstream of TLR9 activation (52). Importantly, results of in silico modeling 96 97 predict LAMP-5 as a cell-surface protein(29). In this report, we demonstrate LAMP5 as being highly expressed and essential for MLL-r leukemias through the regulation of innate 98 immune signaling, and describe its potential as a target for MLL-r specific immunotherapy. 99

100 **Results**

101 LAMP5 is highly expressed in MLL-r leukemias and is a direct target of the MLL-FP

102 To determine genes that are highly expressed in AML and ALL with MLL-rearragements, we compared recently published RNA-seq studies which identified differentially 103 expressed genes between MLL-rearranged and MLL-germline leukemias in both AML 104 and B-ALL samples(46, 53)(Figure 1A). Twenty seven genes were commonly over-105 expressed in MLL-r ALL and AML (Supplemental table 1). Using the In-silico Human 106 Surfaceome tool (http://wlab.ethz.ch/surfaceome/) 5 of these 27 were predicted to be 107 expressed on the cell surface(29) (Supplemental table 1). Of the 5 predicted proteins, 108 Lysosomal Associated Membrane Protein 5 (LAMP-5) stood out for being present in 109 110 multiple previous MLL-r leukemia gene expression studies(34, 35, 44, 45, 54) 111 (Supplemental Figure 1A-B). We further validated the specificity of *LAMP5* expression 112 in MLL-r leukemias by analysing the 1,109 pediatric leukemia patient samples from the 113 St.Jude PeCan Portal which again revealed LAMP5 as significantly overexpressed in both AMLs and ALLs with MLL-rearragements (Figure 1B)(30, 31). To determine if LAMP5 114 115 expression could discriminate between MLL-r leukemia and MLL-Germ leukemia 116 patients, we performed a Receiving Operating Curve (ROC) analysis. LAMP5 achieved a 117 statistically significant AUC (area under the curve) score in both the Microarray Innovations in Leukaemia (MILE) (GSE13159) and the St. Jude PeCan datasets, with 118 119 high sensitivity and specificity at the optimal cutoff points (Figure 1C). Further, a Kaplan-Meier survival analysis of B-ALL and AML patients correlated higher expression of 120 LAMP5 with poor survival (Supplemental Figure 2). High levels of LAMP5 mRNA 121 expression (Figure 1D) and protein (Figure 1E) were also observed in human myeloid 122

and lymphoid MLL-r leukemia cell lines (MOLM-13, MV4;11, THP-1, and RS4;11) as
 compared to MLL-Germ leukemia cell lines (HL-60, Kasumi-1, K562, REH and RCH ACV) and normal human CD34-enriched cord blood cells (CB-CD34⁺ cells).

Translocations of the MLL locus generate MLL-fusion proteins (MLL-FP) which activate 126 transcription of downstream target genes(55–58). To determine if LAMP5 expression was 127 dependent on the MLL-FP, we transformed CB-CD34⁺ cells with a retrovirus carrying a 128 tetracycline-repressible MLL-AF9 construct. Treatment of transformed cells with 129 Doxycycline led to a simultaneous reduction in the levels of both *MLL-AF9* and *LAMP5*. 130 (Figure 1F). To determine if the MLL-FP directly activates the LAMP5 gene locus, we 131 132 interrogated previously published MLL-AF4 chromatin immunoprecipitation sequencing (ChIP-seq) datasets derived from the RS4;11 cell line, and those from CD34⁺ cells 133 transformed with FLAG-MLL-AF4. Coincident ChIP-seg signals of MLL N-terminus and 134 AF4 C-terminus showed MLL-FP binding at the promotor region of LAMP5(55, 56, 58). 135 Additionally, there was accompanying significant enrichment of H3K4me3 and 136 H3K79me2 at the gene locus, confirming that LAMP5 is a direct target of the MLL-FP 137 complex (Figure 1G). In mice, Lamp5 is not expressed in blood, as it is in human 138 139 (Supplemental Figure 3A-B). Furthermore, we did not detect upregulation of Lamp5 in 140 mouse models of MLL-AF9, E2A-HLF and AML1-ETO leukemia, hence we focused our studies exclusively on human cells (Supplemental Figure 3C). 141

142 LAMP-5 is required for *in vitro* and *in vivo* leukemia cell survival

The ideal immunotherapy target should be essential for the survival of MLL-r leukemias. To test the functional role of LAMP-5 in MLL-r leukemia, we transduced both MLL-r leukemia (MOLM-13, MV4;11, RS4;11, THP-1) and MLL-Germ leukemia cells (Kasumi-1

and REH) with lentiviral shRNA vectors targeting LAMP5. We obtained efficient 146 knockdown of *LAMP5* with 2 independent hairpins as compared to non-targeting control 147 (NT) (Supplemental Figure 4A). Upon LAMP5 depletion, we observed a significant 148 reduction of cell growth in MLL-r leukemia cell lines (Figure 2A), while no effect was seen 149 in MLL-Germ/LAMP-5-negative leukemia cell lines, Kasumi-1 and REH (Figure 2B). 150 Additionally, LAMP5 knockdown led to a significant decrease in colony forming units 151 (CFU) in the MLL-r leukemia cell lines (Figure 2C) suggesting an effect on the 152 clonogenicity of these cells. Furthermore, LAMP5 knockdown led to apoptosis in MLL-r 153 154 leukemia cells, as evident by a significant increase in Annexin V and 7-AAD double positive staining (Figure 2D; Supplemental Figure 4B). We next sought to determine the 155 role of LAMP-5 in leukemia propagation in vivo. MV4;11 cells were transduced with 156 shRNAs targeting either LAMP5 or a NT control followed by transplantation into 157 immunocompromised NOD-Rag1^{null} IL2ry^{null} (NRG) mice (8 mice per shRNA group). Viral 158 transduction was confirmed by flow cytometry for Venus expression. Four weeks after 159 transplantation, mice developed signs of leukemia and were sacrificed. In the bone 160 marrow, both groups showed similar human cell engraftment based on human CD45 161 expression. On the other hand, the transduced Venus⁺ fraction was significantly reduced 162 in shLAMP5-2 compared to shNT mice. (Figure 2E, left panels). We repeated this 163 experiment using cells from a patient with MLL-r (MLL-AF10) leukemia. We again 164 165 observed significant reduction in the proportion of Venus⁺ cells with LAMP5 knockdown compared to NT control (Figure 2E, right panels). Overall, these data underscore a 166 167 critical role for LAMP-5 in the growth of MLL-r leukemia cells.

168

169 LAMP-5 is required for activation of TLR/IL1R signaling in leukemia

Acute leukemias exhibiting constitutive activation of innate immune signaling pathways 170 have been characterized as having a pro-inflammatory profile which is required for their 171 survival(59, 60). These physiologic cellular systems involve TLR/IL1R signaling and 172 culminate in the release of pro-inflammatory cytokines via NF-kB and/or of type I 173 interferons (IFN-1)(61). Recent studies reveal heightened activation of NF-kB signaling in 174 175 MLL-r leukemia compared to other leukemias(62). Furthermore, MLL-r leukemias have been shown to require the TLR/IL1R signaling pathway to survive, through degradation 176 of the wild-type MLL protein, allowing the MLL-FP to bind to its target genes without 177 178 restriction(63). Recently, Combes et al. showed that LAMP-5 plays an important role in controlling the subcellular location of TLR9 after activation in human pDC. Upon activation 179 of TLR9, LAMP-5 shuttles TLR9 from the VAMP3⁺-Interferon Response Factor signaling 180 endosome (IRF-SE), to the LAMP-1⁺-pro-inflammatory-signaling endosome (PI-SE). This 181 transition of TLR localization in turn acts as a negative regulator of IFN-1 signaling (52). 182 Based on the known role of LAMP-5 in TLR9 localization in pDCs, we first examined the 183 localization of intracellular LAMP-5 in MOLM-13 cells. We performed co-staining of 184 MOLM-13 cells with antibodies against LAMP-5, LAMP-1 and Myeloid Differentiation 185 Primary Response 88 (MYD88), a scaffold protein that is required for TLR and IL1R 186 signaling (63-65). Confocal microscopy showed that in MLL-r leukemia cells, LAMP-5 187 188 localized to LAMP-1⁺ vesicles. As suspected, we found MYD88 accumulating highly in 189 the periphery of LAMP-1⁺ vesicles in MLL-r leukemia, suggestive of TLR/IL1R activation 190 (Figure 3A). Conversely, in the LAMP-5-negative MLL-Germ leukemia cells (Kasumi-1),

191 MYD88 does not co-localize with LAMP-1⁺ vesicles. However, overexpression of LAMP-192 5 in this cell line led to relocation of MYD88 around LAMP-1⁺ vesicles (**Figure 3B**).

We subsequently hypothesized that LAMP5 loss may dampen TLR/IL1R signaling in 193 MLL-r leukemias. We thus analyzed known effector proteins downstream of TLR/IL1R 194 activation by western blot. Upon LAMP5 knockdown, we observed a reduction in 195 phosphorylated NF-kB, p38, and JNK, key players in the signal transduction downstream 196 197 of TLR/IL1R (Figure 3C). To further determine the impact of LAMP5 depletion on activation of NF-kB downstream of TLR activation, we measured NF-kB activity using the 198 MLL-r cell line THP-1Blue-NF-kB, which contains an NF-kB inducible Secreted Embryonic 199 200 Alkaline Phosphatase (SEAP) reporter. Robust activation of NF-kB was evident in control cells upon incubation with PAM3CSK4 (TLR2 agonist) or LPS (TLR4 agonist). 201 Knockdown of LAMP-5 led to near-complete blockade of this activation, suggesting that 202 TLR-induced NF-kB signaling is disrupted upon LAMP-5 depletion (Figure 3D). 203 Correspondingly, in the LAMP-5 negative cell line Kasumi-1, overexpression of LAMP5 204 led to increased phosphorylation of p38, JNK and NF-kB along with increased cell 205 growth(Figure 3E-F). 206

Previous studies have shown that NF-kB plays a critical role in MLL-r leukemias (62). We thus hypothesized that NF-kB activation would rescue the cell growth defect seen by LAMP5 depletion. We induced persistent activation of NF-kB in leukemia cells by overexpressing a constitutively active version of Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta (IKBKB-EE) in these cells. The IKBKB-EE is a variant of IKBKB that contains mutations at Ser¹⁷⁷ and Ser¹⁸⁸ leading to constant degradation of IkB-α kinase (66, 67). Despite sustained NF-kB activation, knockdown of LAMP-5 in MOLM-13 and

RS4;11 cells still led to growth inhibition, suggesting that loss of NF-kB is not the only 214 signaling event being affected by LAMP5 depletion (Supplemental Figure 5A-B). A 215 potential mechanism underlying this essentially was proposed by Wang et al, where they 216 suggested that loss of LAMP5 in MLL-r leukemia led to degradation of the MLL-FP due 217 to increased autophagy(68). However, in our experiments we did not observe any change 218 in the levels of the MLL-FP in THP1 and MOLM-13 cells upon LAMP-5 depletion 219 (Supplemental Figure 4C). Overall, these results underscore a critical role for LAMP-5 220 in the activation of TLR/IL1R signaling in MLL-r leukemia, while also indicating the 221 222 presence of additional attributes that are also essential.

LAMP-5 is a negative regulator of IFN-1 signaling in MLL-r leukemias

224 Since activation of NF-kB was not sufficient to rescue the cell growth inhibition seen upon 225 LAMP-5 depletion, we next sought to understand the mechanistic significance of the 226 inflammatory-signal-regulation function of LAMP-5 in MLL-r leukemia. In pDCs, the 227 carboxy-terminal YKHM domain of LAMP-5 was found to be required for normal 228 localization of LAMP-5 and for transportation of TLR9 from the early endosome vesicle to 229 the pro-inflammatory vesicle (47, 50, 52). We thus overexpressed wild-type LAMP-5 230 (LAMP-5-WT), a YKHM mutant (LAMP-5-Y276A), or control vector (EV) in MV4;11 and THP-1 cells, followed by selective knockdown of endogenous LAMP5 using an shRNA 231 targeting the 3'UTR region of LAMP5. Overexpression of LAMP-5-WT completely 232 233 prevented the cell growth inhibition upon knockdown of endogenous LAMP5, validating LAMP5 as the main target of the shRNA. In contrast, LAMP-5-Y276A was unable to 234 rescue the cell growth in both MV4;11 and THP-1 cell lines (Figure 5A). In pDCs, LAMP5 235 knockdown or overexpression of LAMP-5-Y276A induced IFN-1 activation upon TLR9-236

stimulation, due to retention of TLR9 in the IRF-SE. To determine the effect of LAMP-5 237 on IFN-1 signaling in MLL-r leukemia, we turned to THP-1-ISG-SEAP cells that contain 238 an Interferon Stimulated Gene (ISG) inducible-SEAP reporter. Upon TLR activation by 239 PAM3CSK4, IFN-1 signaling activation was evident only in the LAMP-5-depleted cells but 240 not in the control LAMP-5 depleted condition (Figure 5B). To ensure this effect was not 241 242 limited to one cell line, we validated the increase in IFN-1 signaling in other MLL-r cell lines by demonstrable increased expression of Interferon Regulatory Factor 7 (IRF7), one 243 of the downstream effectors of TLR activation, Interferon Alpha 2 (IFNA2) and Signal 244 transducer and activator of transcription 1 (STAT1) upon depletion of LAMP-5 (Figure 245 5C) (69). To assess the role of LAMP5-depletion mediated IFN-1 activation on cell growth, 246 we performed knockdown of IRF7 along with LAMP5 in MV4;11 cells. We found that loss 247 of IRF7 alone had no significant effect on MLL-r leukemia cell growth but importantly, its 248 depletion prevented the growth inhibition observed upon LAMP-5 knockdown (Figures 249 5D and 5E) (Supplemental Figure 6A-B). Collectively, these results demonstrate that a 250 critical function of LAMP-5 in MLL-r leukemias is to promote the transfer of TLR/IL1R from 251 the IFN-1-activating signaling cascade to the pro-inflammatory signaling cascade. 252 253 Depletion of LAMP-5 thus leads not only to loss of NF-kB activation but also to activation of IFN-1-signaling, the latter inducing cell-death. 254

255 Surface LAMP-5 can be detected and targeted with Antibody Drug Conjugate 256 therapy

Previous studies have shown that all LAMP family members can localize to the plasma membrane (70–73). Furthermore, LAMP-5 was found to briefly localize in the plasma membrane of cortical neurons in mice, and is highly predicted to reach the cell membrane

based on the human surfaceome(29, 47). We thus sought to confirm if LAMP-5 was 260 expressed on the surface of MLL-r leukemia cells. Using an antibody targeting the N-261 terminus of LAMP-5, we were able to detect LAMP-5 on the surface of MLL-r leukemia 262 cell lines, while none was detected in the MLL-Germ leukemias (Figure 5A-B). To 263 validate the specificity of the antibody, we overexpressed LAMP-5 or control empty vector 264 (EV) in the LAMP-5-negative MLL-Germ leukemia cell line, Kasumi-1. We detected 265 surface LAMP-5 only in the cells that express high levels of LAMP-5 (Figure 5C). Using 266 primary AML patient samples, we further validated that surface LAMP-5 can discriminate 267 268 between MLL-r leukemia and MLL-Germ leukemias (Figure 5D). As proof-of-concept for potential therapeutic use, we used a secondary antibody conjugated to the tubulin-toxin 269 Mertansine, targeting the surface-LAMP-5 antibody. We observed that a 72-hour 270 treatment with this antibody-sandwich comprised of the surface LAMP-5 antibody along 271 with the secondary ADC antibody is sufficient to reduce cell viability in MLL-r leukemia 272 cell lines MOLM-13, RS4;11 and THP-1, while no effect was seen in the LAMP-5-negative 273 Kasumi-1 cell line (Figure 5E). These results suggest that LAMP-5 could be exploited as 274 a MLL-r specific biomarker and could potentially be used as a target for immunotherapy. 275

276 **Discussion**

Our findings identify *LAMP5* as a novel core gene in MLL-r leukemias, directly upregulated by the MLL-FP. Additionally, we found that LAMP-5 is essential for MLL-r leukemia cell survival. Further, we found that one of the critical functions of LAMP-5 is to regulate innate-immune signaling in MLL-r leukemias, specifically directing the flux of activity away from IRF-SE towards the PI-SE, leading to constant activation of NF-kB.

Recent discoveries have highlighted how the specific subcellular location and timing of 282 TLR activation affect signaling outcomes in normal immune cells(74). However, how 283 these mechanisms function in leukemia is still poorly understood. Recently, Combes et 284 al. showed that LAMP-5 is a negative regulator of IFN-1 signaling in pDCs by transporting 285 activated TLR9 from the IRF-SE to the PI-SE. Although dispensable for pDCs cell 286 287 survival, LAMP-5 depletion leads to unrestricted activation of IFN-1 signaling. Furthermore, aberrant expression of LAMP-5 can lead to diminished activation of pDCs 288 in tumors and contribute to their immunomodulatory phenotype by decreasing the IFN-1 289 290 production capacity(52). Innate immune signaling and inflammation have been shown to play a crucial role in acute leukemias(59, 60). MLL-r leukemias rely on activation of NF-291 kB downstream of TLR/IL1R to maintain the MLL-FP gene signature and block cell 292 differentiation (62, 63). Furthermore, it has been shown that treatment with IFN- β or 293 activation of IFN-1 signaling is deleterious for MLL-r leukemias (75). In our study, we 294 describe a novel role for LAMP-5 in maintaining NF-kB activation and blocking IFN-1 295 signaling downstream of TLR/IL1R activation in MLL-r leukemias. We show that LAMP-5 296 acts as a molecular switch to maintain TLR/IL1R signaling in the pro-inflammatory 297 endosome leading to NF-kB activation, whereas LAMP-5 depletion leads to activation of 298 IFN-1 signaling and cell death. This suggests that both LAMP-5-mediated induction of 299 300 pro-inflammatory signaling and inhibition of IFN-1 signaling contribute to the pathogenesis of MLL-r leukemias. We confirmed that activated IFN-1 signaling upon LAMP-5 depletion 301 induced cell death by depleting IRF7, which rescued cell growth and clonogenicity in 302 303 LAMP5-depleted cells. This suggests that increased IFN-1 signaling is at least partly responsible for inducing cell death upon LAMP-5 depletion. Additionally, overexpression 304

305 of *LAMP5* in MLL-Germ leukemia leads to increased activation of NF-kB, p38 and JNK, 306 and increased cell growth, which suggests that this signaling pathway might be 307 contributing to the therapy-resistant phenotype of MLL-r leukemias.

LAMP-5 is part of the lysosomal associated membrane protein family, of which two main 308 members LAMP-1 and LAMP-2 are expressed in the endo-lysosomal vesicles 309 ubiquitously in all tissues (76). In contrast, LAMP-3 and CD68 (LAMP-4, microsialin) show 310 311 a more restricted expression in human tissues (72, 77). Regardless of their prominent localization in the endo-lysosomal compartment of cells, all LAMP members have been 312 shown to localize in the plasma membrane either at steady state or as a result of immune 313 314 activation(70–73). In humans, LAMP5 expression is generally restricted to the brain, ovaries and blood. In blood, LAMP5 is exclusively expressed in nonactivated pDCs (50, 315 51). Interestingly, in non-activated pDCs, LAMP-5 is found in the ERGIC compartment 316 and it requires the activation of TLR9 to leave the compartment and join the endo-317 lysosomal vesicles(50, 52). We found that the aberrant increased expression of LAMP-5 318 in MLL-r leukemia leads to its accumulation in the plasma membrane, as evidenced by a 319 novel LAMP-5 antibody targeting the N-terminus of the protein. The detection of LAMP-5 320 321 on the surface of MLL leukemias provides the opportunity to potentially use it as a target 322 for immunotherapy in this treatment-refractory malignancy. These results provide a rationale to develop immunotherapies targeting LAMP-5. Furthermore, LAMP5 is highly 323 324 expressed in other cancers such as multiple myeloma (MM) and blastic plasmacytoid 325 dendritic cell neoplasm (BPDCN)(78, 79). Therefore LAMP5 immunotherapies could 326 benefit other blood diseases. Finally, total loss of Lamp5 in mice had no major effects on

health or lifespan with minor behavioral effects, suggesting that there could be a wide
therapeutic window for LAMP-5-directed therapies in humans (48, 49).

Similar to our observations, Wang et al. recently showed that LAMP-5 is essential for the 329 survival of MLL-r leukemias in vitro and in vivo using shRNA knockdown. However, they 330 propose that LAMP-5 is a negative regulator of autophagy leading to MLL-FP 331 stabilization. They show that LAMP-5 and ATG5 colocalize in MLL-r leukemia cells and 332 333 that blockade of autophagy is sufficient to rescue the increased levels of apoptosis after LAMP-5 knockdown(68). We were unable to detect any significant change in the levels 334 of the MLL-FP upon LAMP5 knockdown. Since TLR-mediated innate immune signaling 335 336 can regulate autophagy, it is possible that the function of LAMP-5 in regulating autophagy as described by Wang et al is downstream of its impact on endosome-lysosome 337 trafficking(80–84). On the other hand, it is also possible that these effects are not directly 338 linked and that LAMP-5 might exert its growth-promoting effects in MLL-r leukemia by 339 340 multiple mechanisms. It is notable however that the role of autophagy in leukemia is controversial(85). In murine MLL leukemia models, heterozygous loss of Atg5 leads to 341 increased leukemia cell proliferation in vitro and more aggressive leukemia in vivo, while 342 343 homozygous loss is lethal to these cells(86). Additionally, while some studies suggest 344 that Atg5-dependent autophagy may contribute to the development of MLL-AF9 driven 345 leukemia but dispensable for propagation and chemosensitivity, others suggest that Atg5dependent autophagy is dispensable altogether(87–89). Overall, our results show that 346 347 LAMP-5 localizes both on the surface and in LAMP-1⁺ endosomes in leukemia, leading to constitutive activation of pro-inflammatory signaling, and dampening of interferon-348 signaling, and that it can be used as a target for immunotherapy. 349

350 Materials and Methods:

351 Cell lines and primary patient cells

Human leukemia cell lines were maintained in Iscove's modified Dulbecco medium
(IMDM) or Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10%
fetal bovine serum (FBS), 1% penicillin and 1% streptomycin.

MLL-AF9 Tet-off human CD34⁺ cells were a kind gift from Dr. James Mulloy, and were 355 356 generated as follows: umbilical cord blood (UCB) was obtained from the Translational 357 Trial Development and Support Laboratory of CCHMC. CD34⁺ cells were isolated from UCB using the EasySep CD34⁺ isolation kit (StemCell Technologies). CD34⁺ cells were 358 pre-stimulated in IMDM/20%FBS containing 100ng/mL SCF, TPO, Flt3-L, and IL-6 and 359 360 20ng/mL IL-3 for 2 days before transduction. Transduction was carried out using spinoculation onto Retronectin (Takara Bio) coated plates along with 4ug/mL polybrene. 361 Cells were transduced with both the pSIN-TREtight-dsRED-MLL/AF9 lentivirus and the 362 MSCV-GFP-IRES-tTA34 retrovirus. After transduction, cells were maintained in 363 IMDM/20% FBS with 10ng/mL of each cytokine. A pure population of dsRED⁺GFP⁺ cells 364 were selected over several weeks of culture. 365

Fully de-identified primary patient cells were obtained from the Cincinnati Children's Hospital Medical Center Biorepository. Patient identities have been protected. By the time the mice displayed signs of leukemia, the only human cells that remained in the mice were leukemic cells (MLL-rearrangement was confirmed with FISH).

Human CD34⁺ cells and cells from patients with MLL-r AML were cultured in IMDM
 supplemented with 20% FBS and 10 ng/ml human cytokines including SCF, FLT3-Ligand,

Thrombopoietin, IL-3 and IL-6. Cell lines were periodically validated by STR genotyping through Genetica Cell Line Testing (LabCorp). Cells were tested and were negative for mycoplasma contamination. None of the cell lines utilized in this study are recognized by the ICLAC as being commonly misidentified.

376 Animal experiments

All animals used for this study were 6-12 weeks old. All animal experiments were carried 377 out in accordance with the guidelines of the Institutional Animal Care and Use Committee 378 (IACUC). For xenograft experiments with MV4;11 and MLL-r primary patient cells, 379 immunocompromised NOD-Rag1^{null} IL2ry^{null} (NRG) (Jackson Laboratories, stock no. 380 007799) recipient mice were conditioned with 30 mg/kg busulfan and transplanted with 2-381 7.5x10⁵ cells 24 hours later. In xenograft experiments bone marrow samples were 382 383 collected four weeks after transplantation as well as when signs of leukemia were present; 384 aspirates were analyzed via flow cytometry for the presence of human CD45⁺ cells and 385 the presence of shRNA-transduced Venus⁺ cells

386 **Retroviral and lentiviral transductions**

Retroviral and lentiviral supernatants were generated by transfection of HEK293T cells using the FuGENE 6 reagent (Promega) according to the manufacturer's recommendations.

The lentiviral shRNA pLKO.1-Puro plasmids TRCN0000129410 (shLAMP5-1), TRCN0000129378 (shLAMP5-2) and TRCN0000014861 (shIRF7) were purchased from Millipore Sigma. Human cells were incubated with a single dose of lentiviral supernatant overnight. Cells transduced with constructs granting puromycin resistance were selected

in 0.5-5 ug/ml of Puromycin for 72 hours. Cells transduced with constructs containing a
 fluorescent marker (Venus) were isolated on between days 4-5 after transduction by
 sorting using MoFlo XDP, FACSAria (BD Biosciences) or a SONY SH800S (Sony
 Biotechnology

The retroviral IKBKB-S177E-S181E (IKBKB-EE) plasmid was a gift from Anjana Rao (Addgene plasmid # 11105; http://n2t.net/addgene:11105; RRID:Addgene_11105). Flag-LAMP5-WT and Flag-LAMP5-Y276A plasmids were as described previously(47) FLAG-LAMP5-WT and FLAG-LAMP5-Y276A were cloned into the MSCV-IRES-Puro vector.

402 Flow cytometry

For apoptosis assays, cells were incubated with allophycocyanin (APC)-conjugated Annexin V (BD Bioscience) for 15 minutes at RT in 1X Annexin V Binding Buffer (BD Bioscience) followed by staining with 7-aminoactinomycin (7-AAD) (eBioscience). For surface LAMP-5 detection, cells were incubated with 3 μg anti-human LAMP-5 therapeutic antibody (TAB-0643CL, Creative Biolabs, NY, USA) overnight and then stained with anti-mouse IgG1-PE (eBioscience). Data were acquired on a FACS Canto I and results were analyzed using FlowJo Version 10 (FlowJo).

410 **Colony-forming unit assays**

Transduced human cells were sorted 4-5 days after transduction and were cultured in methylcellulose-containing media (StemCell Technologies, H4434). Colonies were scored 10-14 days after plating.

414

415

416 **RT- and Quantitative RT-PCR**

Total RNA was extracted from human Puromycin-selected or sorted Venus⁺ cells using 417 the RNeasy Mini kit (Qiagen). RNA was reversed transcribed into cDNA using iScript 418 Advanced cDNA Synthesis kit (Bio-Rad Laboratories). For Quantitative RT-PCR 5-10ng 419 of cDNA was analyzed using iTaq Universal SYBR Green Supermix and iTaq Universal 420 Probes Supermix (Bio-Rad) in a StepOnePlus Real-Time PCR machine (Applied 421 422 Biosystems). Tagman probes were purchased from Applied BioSystems. Primers and for Quantitative **RT-PCR** LAMP5 423 probes used were: (5'-TACGACTCCTCGGAGAAAACC-3' and 5'-TGACACTCATAGGACTTCCCAG-3') IRF7 424 425 (5'-CCCACGCTATACCATCTACCT-3' and 5'-GATGTCGTCATAGAGGCTGTTG-3'), LAMP5(Hs00202136 m1), STAT1 (Hs01013996 m1), IFNA2 (Hs00265051 s1), ACTIN 426 (Hs99999903-m1) 427

428 Western blotting

The primary antibodies used were anti-LAMP-5 (Thermo Fisher Scientific Cat# 14-9778-429 80, RRID:AB 2573029), anti-AF9 (Bethyl Cat# A300-597A, RRID:AB 495520), anti-430 MLL1 (Cell Signaling Technology Cat# 14689, RRID:AB 2688009), anti-phospho-JNK 431 (Cell Signaling Technology Cat# 4668, RRID:AB 823588), Phospho-IKK (Cell Signaling 432 433 Technology Cat# 2697, RRID:AB 2079382), Phospho-p38 MAPK (Cell Signaling Technology Cat# 4511, RRID:AB 2139682), Phospho-NF-kB p65 (Cell Signaling 434 Technology Cat# 4025, RRID:AB 10827881), anti-Actin (Cell Signalling Technology, 435 13E5, RRID: AB 2223172), and anti- β -tubulin (Cell Signaling Technology, 9F3, RRID: 436 AB 823664). Whole cell lysates were isolated using RIPA buffer (Sigma) and the amount 437 of protein was determined using the BCA Protein Assay Kit (Thermo Scientific). 30 µg of 438

protein was separated by SDS-PAGE on a 4-20% gradient gel (Bio-Rad). After transfer
to PVDF membranes, blots were blocked with Odyssey® Blocking Buffer TBS (LI-COR)
for one hour and incubated with primary antibodies overnight. After washing, blots were
incubated with appropriate secondary IRDye 680RD goat anti-mouse (LI-COR) and
IRDye 800CW goat anti-rabbit (LI-COR) antibodies at a dilution of 1:10,000 for one hour.
Images were obtained using the Odyssey CLx Infrared Imaging System (LI-COR).

445 ChIP-seq Analysis

ChIP-seq data were downloaded from the Gene Expression Omnibus using the listed accession numbers (GSE84116 for MLL-Af4 transformed CB CD34⁺, GSE95511 for ML-2 data, GSE79899 for MV4;11 and THP-1 data, GSE38403 for RS4;11 data, and GSE38338 for SEM data) and visualized with the UCSC Genome Browser, assembly hg19. For consistency, data for RS4;11 and SEM were converted from their originally mapped hg18 to hg19 using the liftOver tool from the UCSC Genome Browser Utilities.

452 **Cell Viability**

453 MOLM-13, RS4;11, THP-1 and Kasumi-1 cells were plated at 10,000 cells per well in a 454 96-well plate. Cells were incubated with LAMP-5 therapeutic antibody (TAB-0643CL 455 Creative Biolabs) and Anti-Mouse IgG Fc-DM1 Antibody with Non-Cleavable Linker (AM-456 103D1-50, Moradec LLC) at 5ng/uL and 1ng/uL final concentrations respectively. To 457 measure cell viability CellTiter-Glo® 2.0 Cell Viability Assay (Promega Cat# G9242 WI, 458 USA) was used following manufacture protocol.

459

460

461 SEAP reporters

THP-1-Blue NF-kB/ISG cells (InvivoGen) carrying a stable integrated NF-kB-inducible or 462 ISG-inducible secreted embryonic alkaline phosphatase (SEAP) reporter construct were 463 transduced with shLAMP5-2-Venus and sorted for Venus expression after 48 hours. Cells 464 were then plated at a concentration of 2x10⁴ cells/well and stimulated with Pam3CSK4 465 (10ng/mL) or LPS (100ng/mL) for 24 hours. Cells were centrifuged and 20uL supernatant 466 467 was incubated with 180uL QUANTI-Blue reagent at 37 degrees for 30 min - 2 hours. The levels of NF-κB-induced or ISG-induced SEAP was measured in a microplate reader at 468 620 nm. 469

470 Immunoflorescence

471 Cells seeded on alcian blue-treated coverslips were fixed with 3.5% PFA and 472 permeabilized with 0.05% saponin. Cells were then stained overnight with primary antibodies: anti-LAMP-5 (Thermo Fisher Scientific Cat# 14-9778-80, 473 RRID:AB 2573029), anti-MYD88 (R and D Systems Cat# AF2928, RRID:AB 2297977), 474 475 anti-LAMP-1 BV421 (BioLegend Cat# 328626, RRID:AB 11203537) anti-LAMP-2 AF647 (Thermo Fisher Scientific Cat# A15464, RRID:AB 2534477). Immunofluorescence and 476 confocal microscopy was performed with a Zeiss LSM580 63x objective and 477 478 accompanying imaging softwares

479 **Statistics**

The statistical methodology used and sample sizes are described in the individual Figure
legends. *t* tests were two tailed unless otherwise stated. Results are presented as mean
± SEM unless otherwise stated. A two-sided time-stratified Cochran-Mantel-Haenszel

483 was used for the Kaplan-Meier Survival analysis. ROC curves were used to determine 484 the diagnostic utility of LAMP5 mRNA. The sensitivity and specificity were identified at the 485 optimal cutoff point that was chosen at which the Youden's index was maximal. A 486 significance level cutoff of 0.05 was used unless otherwise stated. Statistical analysis was 487 performed using GraphPad Prism.

488 Authors Contributions:

G.G.M., L.H.L., and A.R.K. contributed to study conception and design. G.G.M., J.C., and
D.L. acquired data. G.G.M., J.C., M.W., M.B., D.L., P.P., E.G., and L.H.L. analyzed and
interpreted data. G.G.M., J.C., L.H.L. and A.R.K. wrote and revised the manuscript. M.W.,
D.L., P.P., E.G., reviewed the manuscript. M.W., D.L., and J.C., provided administrative,
technical or material support.

494 **Acknowledgments**:

We would like to thank Daniel Starczcynowski, PhD, for his intellectual input. We would like to acknowledge the assistance of the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center. All flow cytometric data were acquired using equipment maintained by the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center.

500 M.W. was supported by an NIH grant (R50 CA211404). L.H.L. is a St. Baldrick's 501 Foundation Scholar and is supported by grants from CancerFree KIDS and the NIH (L40 502 HL143713-01) A.R.K. was supported by a Hyundai Hope on Wheels grant.

503

504

505 **References**

- 1. Ziemin-van der Poel S et al. Identification of a gene, MLL, that spans the breakpoint
- in 11q23 translocations associated with human leukemias. [Internet]. Proc. Natl. Acad.
- 508 *Sci.* 1991;88(23):10735–10739.
- 2. Djabali M et al. A trithorax–like gene is interrupted by chromosome 11q23
- translocations in acute leukaemias [Internet]. *Nat. Genet.* 1992;2(2):113–118.

3. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax

- 512 by 11q23 chromosomal translocations in acute leukemias [Internet]. *Cell*
- 513 1992;71(4):691–700.
- 4. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias.. *Leukemia*1995;9:762–769.
- 516 5. Greaves MF. Infant leukaemia biology, aetiology and treatment. [Internet]. *Leukemia* 517 1996;10(2):372–7.
- 6. Meyer C et al. The MLL recombinome of acute leukemias in 2017 [Internet].
- 519 *Leukemia* 2018;32(2):273–284.
- 520 7. Hilden JM et al. Analysis of prognostic factors of acute lymphoblastic leukemia in
- infants: report on CCG 1953 from the Children's Oncology Group. [Internet]. *Blood*2006;108(2):441–51.
- 523 8. Pieters R et al. A treatment protocol for infants younger than 1 year with acute
- 524 lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre
- ⁵²⁵ randomised trial. [Internet]. *Lancet* 2007;370(9583):240–50.
- 526 9. Bauer J et al. Antigen Targets for the Development of Immunotherapies in Leukemia

- 527 [Internet]. Int. J. Mol. Sci. 2019;20(6):1397.
- 10. Rossi JG et al. Lineage switch in childhood acute leukemia: An unusual event with
 poor outcome [Internet]. *Am. J. Hematol.* 2012;87(9):890–897.
- 11. Jacoby E et al. CD19 CAR immune pressure induces B-precursor acute
- 531 lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- 532 [Internet]. *Nat. Commun.* 2016;7(1):12320.
- 12. Moschiano E, Raca G, Fu C, Pattengale PK, Oberley MJ. Congenital B-
- 534 lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution
- to mixed phenotype acute leukemia [Internet]. *Leuk. Res. Reports* 2016;6:29–32.
- 13. Rayes A, McMasters RL, O'Brien MM. Lineage Switch in MLL-Rearranged Infant
- 537 Leukemia Following CD19-Directed Therapy [Internet]. *Pediatr. Blood Cancer*

538 2016;63(6):1113–1115.

- 14. Haddox CL et al. Blinatumomab-induced lineage switch of B-ALL with
- t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch
- 541 phenotypic, cytogenetic and molecular analysis [Internet]. Blood Cancer J.

542 2017;7(9):e607–e607.

- 15. Balducci E et al. Lineage switch from B acute lymphoblastic leukemia to acute
- 544 monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under
- 545 CD19-targeted therapy [Internet]. Ann. Hematol. 2017;96(9):1579–1581.
- 16. Wölfl M et al. Spontaneous reversion of a lineage switch following an initial
- 547 blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL [Internet].
- 548 Blood Adv. 2018;2(12):1382–1385.

549	17. Aldoss I, Song JY. Extramedullary relapse of KMT2A(MLL)-rearranged acute
550	lymphoblastic leukemia with lineage switch following blinatumomab [Internet]. Blood
551	2018;131(22):2507–2507.

- 18. He RR et al. Immunotherapy- (Blinatumomab-) Related Lineage Switch of
- 553 KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid

554 Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute

Leukemia [Internet]. Case Rep. Hematol. 2019;2019:1–4.

19. Duffner U et al. The possible perils of targeted therapy [Internet]. *Leukemia*2016;30(7):1619–1621.

20. Winters AC, Bernt KM. MLL-Rearranged Leukemias—An Update on Science and

559 Clinical Approaches [Internet]. Front. Pediatr. 2017;5. doi:10.3389/fped.2017.00004

21. Wei J et al. Microenvironment Determines Lineage Fate in a Human Model of MLL-

561 AF9 Leukemia [Internet]. *Cancer Cell* 2008;13(6):483–495.

562 22. Cohen A, Petsche D, Grunberger T, Freedman MH. Interleukin 6 induces myeloid

563 differentiation of a human biphenotypic leukemic cell line [Internet]. *Leuk. Res.*

564 1992;16(8):751–760.

565 23. Bock T, Bausch-Fluck D, Hofmann A, Wollscheid B. CD proteome and beyond -

technologies for targeting the immune cell surfaceome. [Internet]. Front. Biosci.

567 (Landmark Ed. 2012;17(1):1599–612.

- 24. Hofmann A et al. Proteomic cell surface phenotyping of differentiating acute myeloid
 leukemia cells [Internet]. *Blood* 2010;116(13):e26–e34.
- 570 25. Strassberger V et al. A comprehensive surface proteome analysis of myeloid

- 571 leukemia cell lines for therapeutic antibody development [Internet]. *J. Proteomics*572 2014;99:138–151.
- 573 26. Hu CW et al. A quantitative analysis of heterogeneities and hallmarks in acute
- 574 myelogenous leukaemia [Internet]. *Nat. Biomed. Eng.* 2019;3(11):889–901.
- 575 27. Mirkowska P et al. Leukemia surfaceome analysis reveals new disease-associated
- 576 features [Internet]. *Blood* 2013;121(25):e149–e159.
- 577 28. Bausch-Fluck D et al. A Mass Spectrometric-Derived Cell Surface Protein Atlas
- 578 [Internet]. *PLoS One* 2015;10(4):e0121314.
- 579 29. Bausch-Fluck D et al. The in silico human surfaceome [Internet]. *Proc. Natl. Acad.*580 *Sci.* 2018;115(46):E10988–E10997.
- 30. Zhou X et al. Exploring genomic alteration in pediatric cancer using ProteinPaint
- 582 [Internet]. *Nat. Genet.* 2016;48(1):4–6.
- 583 31. Ma X et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric
- leukaemias and solid tumours [Internet]. *Nature* 2018;555(7696):371–376.
- 32. Haferlach T et al. Clinical Utility of Microarray-Based Gene Expression Profiling in
- the Diagnosis and Subclassification of Leukemia: Report From the International
- 587 Microarray Innovations in Leukemia Study Group [Internet]. J. Clin. Oncol.
- 588 2010;28(15):2529–2537.
- 33. Armstrong SA et al. MLL translocations specify a distinct gene expression profile
- that distinguishes a unique leukemia [Internet]. *Nat. Genet.* 2002;30(1):41–47.
- 34. Zangrando A, Dell'Orto MC, te Kronnie G, Basso G. MLL rearrangements in
- 592 pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage

- specific signatures [Internet]. *BMC Med. Genomics* 2009;2(1):36.
- 594 35. Ross ME et al. Gene expression profiling of pediatric acute myelogenous leukemia.
- 595 [Internet]. *Blood* 2004;104(12):3679–87.
- 596 36. Kroon E et al. Hoxa9 transforms primary bone marrow cells through specific
- collaboration with Meis1a but not Pbx1b [Internet]. *EMBO J.* 1998;17(13):3714–3725.
- 598 37. Shen WF et al. AbdB-like Hox proteins stabilize DNA binding by the Meis1
- 599 homeodomain proteins. [Internet]. *Mol. Cell. Biol.* 1997;17(11):6448–6458.
- 38. Lawrence HJ et al. Mice bearing a targeted interruption of the homeobox gene
- 601 HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. [Internet].
- 602 *Blood* 1997;89(6):1922–30.
- 39. Lawrence HJ et al. Loss of expression of the Hoxa-9 homeobox gene impairs the
 proliferation and repopulating ability of hematopoietic stem cells. [Internet]. *Blood*
- 605 2005;106(12):3988–94.
- 40. Kumar AR et al. Hoxa9 influences the phenotype but not the incidence of MII-AF9
 fusion gene leukemia. *Blood* 2004;103(5):1823–1828.
- 41. Unnisa Z et al. Meis1 preserves hematopoietic stem cells in mice by limiting
 oxidative stress. [Internet]. *Blood* 2012;120(25):4973–81.
- 42. Kumar AR et al. A role for MEIS1 in MLL-fusion gene leukemia. [Internet]. *Blood*2009;113(8):1756–8.
- 43. Roychoudhury J et al. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion
 gene leukemia. [Internet]. *Blood* 2015;125(16):2544–52.

614	44. Valk PJ et al. Prognostically Useful Gene-Expression Profiles in Acute Myeloid	
615	Leukemia [Internet]. <i>N. Engl. J. Med.</i> 2004;350(16):1617–1628.	
616	45. Stam RW et al. Gene expression profiling-based dissection of MLL translocated and	
617	MLL germline acute lymphoblastic leukemia in infants [Internet]. Blood	
618	2010;115(14):2835–2844.	
619	46. Lavallée V-P et al. The transcriptomic landscape and directed chemical interrogation	
620	of MLL-rearranged acute myeloid leukemias [Internet]. Nat. Genet. 2015;47(9):1030–	
621	1037.	
622	47. David A et al. BAD-LAMP defines a subset of early endocytic organelles in	
623	subpopulations of cortical projection neurons [Internet]. J. Cell Sci. 2007;120(2):353-	
624	365.	
625	48. Tiveron M-C et al. LAMP5 Fine-Tunes GABAergic Synaptic Transmission in Defined	
626	Circuits of the Mouse Brain [Internet]. <i>PLoS One</i> 2016;11(6):e0157052.	
627	49. Koebis M et al. LAMP5 in presynaptic inhibitory terminals in the hindbrain and spinal	
628	cord: a role in startle response and auditory processing [Internet]. Mol. Brain	

2019;12(1):20. 629

50. Defays A et al. BAD-LAMP is a novel biomarker of nonactivated human 630

plasmacytoid dendritic cells [Internet]. Blood 2011;118(3):609-617. 631

51. Villani A et al. Single-cell RNA-seq reveals new types of human blood dendritic 632

633 cells, monocytes, and progenitors [Internet]. Science (80-.). 2017;356(6335):eaah4573.

634 52. Combes A et al. BAD-LAMP controls TLR9 trafficking and signalling in human

plasmacytoid dendritic cells [Internet]. Nat. Commun. 2017;8(1):913. 635

53. Gu Z et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
[Internet]. *Nat. Genet.* 2019;51(2):296–307.

54. Otzen Bagger F et al. BloodSpot: a database of gene expression profiles and

transcriptional programs for healthy and malignant haematopoiesis [Internet]. Nucleic

640 *Acids Res.* 2015;44:917–924.

55. Wilkinson AC et al. RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to

642 Gene Activation through an AF4-MLL Complex Interaction [Internet]. *Cell Rep.*

643 2013;3(1):116–127.

56. Benito JM et al. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2

through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-

646 199 [Internet]. *Cell Rep.* 2015;13(12):2715–2727.

57. Wang Q-F et al. MLL fusion proteins preferentially regulate a subset of wild-type

MLL target genes in the leukemic genome. [Internet]. *Blood* 2011;117(25):6895–905.

58. Lin S et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11)

Pro-B Acute Lymphoblastic Leukemia [Internet]. *Cancer Cell* 2016;30(5):737–749.

59. Mirantes C, Passegué E, Pietras EM. Pro-inflammatory cytokines: Emerging players

regulating HSC function in normal and diseased hematopoiesis [Internet]. *Exp. Cell*

653 *Res.* 2014;329(2):248–254.

60. Hemmati S, Haque T, Gritsman K. Inflammatory Signaling Pathways in Preleukemic
and Leukemic Stem Cells [Internet]. *Front. Oncol.* 2017;7:265.

656 61. Cohen P. The TLR and IL-1 signalling network at a glance [Internet]. *J. Cell Sci.*657 2014;127(11):2383–2390.

- 658 62. Kuo H-P et al. Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
- 659 [Internet]. *Cancer Cell* 2013;24(4):423–437.
- 660 63. Liang K et al. Therapeutic Targeting of MLL Degradation Pathways in MLL-
- 661 Rearranged Leukemia. [Internet]. *Cell* 2017;168(1–2):59-72.e13.
- 662 64. Deguine J, Barton GM. MyD88: a central player in innate immune signaling
- 663 [Internet]. *F1000Prime Rep.* 2014;6:97.
- 664 65. Eriksson M et al. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent
- apoptosis and NFκB-dependent differentiation of AML cells [Internet]. *Blood Adv.*
- 666 2017;1(23):2046–2057.
- 66. Mercurio F. IKK-1 and IKK-2: Cytokine-Activated IB Kinases Essential for NF-B
- 668 Activation [Internet]. *Science (80-.).* 1997;278(5339):860–866.
- 669 67. Cui J et al. NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling
- 670 Pathways [Internet]. *Cell* 2010;141(3):483–496.
- 671 68. Wang W-T et al. Activation of the Lysosome-Associated Membrane Protein LAMP5
- by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation
- in Leukemia [Internet]. *Clin. Cancer Res.* 2019;25(9):2795–2808.
- 674 69. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and
- 675 function [Internet]. *Genes Immun.* 2011;12(6):399–414.
- 70. Kannan K et al. Lysosome-Associated Membrane Proteins h-LAMP1 (CD107a) and
- h-LAMP2 (CD107b) Are Activation-Dependent Cell Surface Glycoproteins in Human
- 678 Peripheral Blood Mononuclear Cells Which Mediate Cell Adhesion to Vascular
- 679 Endothelium [Internet]. *Cell. Immunol.* 1996;171(1):10–19.

680	71. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell
681	surface expression of mouse macrosialin and human CD68 and their role as
682	macrophage receptors for oxidized low density lipoprotein [Internet]. Proc. Natl. Acad.
683	<i>Sci.</i> 1996;93(25):14833–14838.
684	72. de Saint-Vis B et al. A Novel Lysosome-Associated Membrane Glycoprotein, DC-
685	LAMP, Induced upon DC Maturation, Is Transiently Expressed in MHC Class II
686	Compartment [Internet]. Immunity 1998;9(3):325–336.

73. Leone DA et al. Surface LAMP-2 Is an Endocytic Receptor That Diverts Antigen

Internalized by Human Dendritic Cells into Highly Immunogenic Exosomes [Internet]. J. *Immunol.* 2017;199(2):531–546.

690 74. Oosenbrug T, van de Graaff MJ, Ressing ME, van Kasteren SI. Chemical Tools for

691 Studying TLR Signaling Dynamics [Internet]. *Cell Chem. Biol.* 2017;24(7):801–812.

692 75. Tracey L et al. NF-κB activation mediates resistance to IFNβ in MLL-rearranged

acute lymphoblastic leukemia [Internet]. *Leukemia* 2010;24(4):806–812.

76. Furuta K, Yang X-L, Chen J-S, Hamilton SR, August JT. Differential Expression of

the Lysosome-Associated Membrane Proteins in Normal Human Tissues [Internet].

696 Arch. Biochem. Biophys. 1999;365(1):75–82.

- 697 77. Chistiakov DA, Killingsworth MC, Myasoedova VA, Orekhov AN, Bobryshev Y V.
- 698 CD68/macrosialin: not just a histochemical marker [Internet]. Lab. Investig.

699 2017;97(1):4–13.

700 78. Beird HC et al. Features of non-activation dendritic state and immune deficiency in

⁷⁰¹ blastic plasmacytoid dendritic cell neoplasm (BPDCN) [Internet]. *Blood Cancer J.*

702 2019;9(12):99.

- 703 79. Ledergor G et al. Single cell dissection of plasma cell heterogeneity in symptomatic
 704 and asymptomatic myeloma [Internet]. *Nat. Med.* 2018;24(12):1867–1876.
- 80. Xu Y et al. Toll-like Receptor 4 Is a Sensor for Autophagy Associated with Innate
- 706 Immunity [Internet]. *Immunity* 2007;27(1):135–144.
- 81. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control
 autophagy [Internet]. *EMBO J.* 2008;27(7):1110–1121.
- 82. Anand PK et al. TLR2 and RIP2 Pathways Mediate Autophagy of Listeria
- monocytogenes via Extracellular Signal-regulated Kinase (ERK) Activation [Internet]. J.
- 711 Biol. Chem. 2011;286(50):42981–42991.
- 83. Into T, Inomata M, Takayama E, Takigawa T. Autophagy in regulation of Toll-like
- receptor signaling [Internet]. *Cell. Signal.* 2012;24(6):1150–1162.
- 84. Franco LH et al. Autophagy downstream of endosomal Toll-like receptor signaling in
- macrophages is a key mechanism for resistance to Leishmania major infection
- 716 [Internet]. J. Biol. Chem. 2017;292(32):13087–13096.
- 85. Rothe K, Porter V, Jiang X. Current Outlook on Autophagy in Human Leukemia: Foe
- in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions
- 719 [Internet]. Int. J. Mol. Sci. 2019;20(3):461.
- 86. Watson A et al. Autophagy limits proliferation and glycolytic metabolism in acute
- myeloid leukemia [Internet]. *Cell Death Discov.* 2015;1(1):15008.
- 722 87. Liu Q, Chen L, Atkinson JM, Claxton DF, Wang H-G. Atg5-dependent autophagy
- contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse

724	model [Internet].	Cell Death Dis.	2016;7(9):e2361-e2361.
-----	-------------------	-----------------	------------------------

- 88. Sumitomo Y et al. Cytoprotective autophagy maintains leukemia-initiating cells in
- 726 murine myeloid leukemia [Internet]. *Blood* 2016;128(12):1614–1624.
- 89. Chen X et al. Autophagy is dispensable for *Kmt2a/Mll-Mllt3/Af9* AML maintenance
- and anti-leukemic effect of chloroquine [Internet]. *Autophagy* 2017;13(5):955–966.






Figure 1: LAMP5 is highly expressed in MLL-r leukemias and is a direct target of the MLL-fusion 749 protein (MLL-FP). (A) Intersection of published gene expression signatures composed of genes 750 overexpressed in MLL-rearranged AML and ALL when compared to MLL-Germline leukemias. (B) Log2 751 FPKM expression of LAMP5 in AML and ALL pediatric patients with MLL-rearrangement (AML MLL-r, 752 n=36 and ALL MLL-r, n=76) compared to MLL-Germline (AML MLL-G, n=270) (ALL MLL-G, n=727) 753 patients. Data obtained from the St. Jude PeCan Portal and presented as median value with quartiles 754 (t- test, p< 0.0001) (C) Receiving Operating Curve (ROC) analysis showing capacity of LAMP5 to 755 discriminate acute leukemia patients with MLL-Germ or MLL-r leukemias. Data obtained from 756 GSE13159 and St. Jude Pecan Portal (D) Relative expression of LAMP5 in MLL-r leukemia (MV4;11, 757 MOLM-13, KOPN-8, THP-1 and RS4;11) and MLL-Germ leukemia (K562, HL-60, Kasumi-1, REH, 758 RCH-ACV) cell lines. The graph represents relative expression of LAMP5 normalized to B-ACTIN. Data 759 is from 3 biological replicates. *LAMP5* expression in cord blood cells was set as 1.0. Bars show mean 760 ± SEM. (E) Western blot analysis of the LAMP-5 levels in MLL-r leukemia and MLL-Germ leukemia 761 human cell lines. CD34⁺ cord blood cells were used as control. TUBULIN was used as a loading control. 762 (F) Graph represents the relative expression of LAMP5 and MLL-AF9 upon incubation with 763 Doxycycline. Relative expression of LAMP5 and MLL-AF9 normalized to B-ACTIN. (G) ChIP-seq 764 profiles of human ALL cell lines expressing MLL-AF4 show binding of the MLL N-terminus, AF4 C-765 terminus and significant H3K4me3 and H3K79me2 mark in the LAMP5 promoter and gene body. ChIP-766 seq data were obtained for the CB CD34⁺ transformed with MLL-Af4 and RS4;11 from GSE84116 and 767 GSE38403 respectively. 768

769



771	Figure 2: LAMP5 expression is required for MLL-r leukemia survival <i>in vitro</i> and <i>in vivo</i> . (A-B)
772	In vitro growth of MLL-r and MLL-G leukemia cell lines (A) (MOLM-13, MV4;11, RS4;11 and THP-1)
773	and (B) (Kasumi-1 and REH) respectively upon shRNA knockdown of LAMP5. Data are from 3
774	independent experiments, <i>t</i> test, (**,p<0.01, ***, p< 0.001). (C) Colony forming units (CFU) of MV4;11
775	and MOLM-13 cells upon LAMP5 shRNA knockdown. Data are from 3 biological replicates,
776	represented as mean and SEM (**,p<0.01, ***, p< 0.001). (D) Percentage of Annexin ⁺ or Annexin ⁺ /7-
777	AAD ⁺ cells after transduction with shNT, shLAMP5-1 and shLAMP5-2. Data are from 3 biological
778	replicates, represented as mean and SEM of at least 3 experiments. <i>t</i> test, p< 0.01 (E) Plots show
779	percentage of human CD45 ⁺ (upper) and Venus ⁺ cells in the CD45 ⁺ fraction (lower) in MV4;11 (left)
780	and MLL-AF10 primary patient sample (right). Data are from 8 biological replicates for MV4;11 and 5
781	biological replicates for the MLL-AF10 primary patient, represented as mean and SEM. <i>t</i> test, p< 0.01








Figure 3: LAMP-5 is required for activation of TLR/IL1R signaling (A) Representative confocal 806 microscopy images showing MV4;11 cells stained with LAMP-5, LAMP-1 and MYD88. Scale bar = 1µm 807 (B) Confocal microscopy image showing Kasumi-1 cells overexpressing EV or LAMP5 stained with 808 LAMP-5, LAMP-2 and MYD88. Scale bar = 1µm (C) Western blot analysis showing that LAMP-5 809 depletion (shL5) led to a decrease of p-IRAK1, p-p38, p-JNK, and p-NFKB, known downstream targets 810 of TLR signaling. (D) THP-1-Blue-NFKB reporter cell line was treated with PAM3CSK2 10ng/mL or LPS 811 100ng/mL in the presence or absence of LAMP5. Data are from 3 independent experiments t-test, ***, 812 p< 0.001. (E) Western blot analysis showing Kasumi-1 cells with overexpression of EV or LAMP5 813 showing increase activation of p-NFKB, p-p38 and p-JNK. (F) In vitro cell growth of Kasumi-1 cells 814 overexpressing EV or LAMP5. Data are from 3 individual experiments, t-test, ***, p< 0.001. 815

816

817





Figure 4: LAMP5 is a negative regulator of IFN-1 signaling in MLL-r leukemias (A) In-vitro growth of MV4:11 and THP-1 cells overexpressing EV. LAMP-5 WT. or LAMP-5-mut upon shRNA knockdown of LAMP-5. Data are from 3 independent experiments. t-test ***, p< 0.001. (B) THP-1 ISG blue reporter cell line was treated with 10ng/mL PAM3CSK2 in the presence or absence of LAMP-5. Data are from 3 independent experiments. Bars show mean ± SEM. t-test **,p<0.01. (C) Relative expression of LAMP5, IRF7, IFNA2 and STAT1 upon knockdown of LAMP-5 in MOLM-13 cells. The graph represents relative expression of LAMP5. IRF7. IFNA2, and STAT1 normalized to B-ACTIN. Data are from 3 biological replicates. Bars show mean ± SEM. (D) In vitro growth of MV4;11 after LAMP5, or IRF7 or LAMP5 and IRF7 shRNA knockdown. Data are from 3 independent experiments, represented as mean and ±SD. ***, p< 0.001. (E) Colony forming units (CFU) of THP-1 cells upon shRNA knockdown of LAMP-5, IRF7, or LAMP-5 and IRF7 together. Data are from 3 independent experiment, represented as mean and ±SD, t-test **,p<0.01.



859

862


866

Figure 5: Surface LAMP-5 can be detected and targeted with Antibody Drug Conjugate therapy 860


- (A) Representative histogram plots showing LAMP-5 surface expression in MLL-r leukemia (MOLM-861 13, RS4;11, MV4;11, and THP-1) and MLL-Germ leukemia (Kasumi-1, HL-60 and NB4) cell lines (B)
- Graph showing mean fluorescence intensity (MFI) of LAMP-5 surface staining in MLL-r leukemias vs 863
- MLL-Germ leukemias. (C) Representative histogram of LAMP-5 staining in Kasumi-1 expressing EV or 864
- LAMP5, confirming the specificity of the antibody. (D) MFI of LAMP-5 surface expression in MLL-r and 865
- surface LAMP-5 antibody clone D1 and αMFc-NC-DM1 ADC antibody for 72h. Bar graph represents 867

MLL-Germ AML patients. (E) MOLM-13, RS4;11, THP-1 and Kasumi-1 cells were incubated with


cell viability from 3 biological replicates presented as Mean and ±SEM 868




Supplemental Figure 1: (A) Intersection of published gene expression signatures composed of genes overexpressed in MLL-rearranged AML and ALL when compared to other MLL-germline leukemias. **(B)** Log2 microarray expression of *LAMP5* in multiple molecular subtypes of leukemia from the Microarray Innovations in Leukemia (MILE) Study. Data shown as median values and quartiles. Normalized data from Bloodspot.eu




Supplemental Figure 2: (A) Kaplan-Meier Event-free survival curve of B-ALL patients based on *LAMP5* Log₂(FPKM) expression (n=1,104 two-sided time-stratified Cochran–Mantel–Haenszel test p=0.003). Data obtained from the St. Jude PeCan Portal. (**B)** Kaplan-Meier Overall survival curve of AML patients based on *LAMP5* (TPM) expression (n=374 two-sided time-stratified Cochran–Mantel–Haenszel test p=0.0014). Data obtained from the Leucegene Data Portal.




Supplemental Figure 3: (A) Normalized Microarray expression data of LAMP5 in human blood and leukemia (THP-1 as MLL-AF9 control). Data from Immuno-Navigator portal, presented as Mean with SD. **(B)** Normalized Microarray expression data of *Lamp5* in mouse blood. Data from Immuno-Navigator portal, presented as Mean with SD. **(C)** Western blot analysis of LAMP-5 expression in Mouse Lin(-) cells transformed with E2A-HLF, AML1-ETO, MLL-AF9. MV4-11 and MOLM-13 cells were used as control.




Supplemental Figure 4: (A) Western blot analysis of LAMP-5 expression in MV4;11 and MOLM-13 cells after transduction of shLAMP5-1 and shLAMP5-2. **(B)** Representative contour plot of MOLM-13 cells after transduction with shNT and shLAMP5-2.



Supplemental Figure 5: (A) Western blot analysis showing overexpression of IKKB-EE (FLAG) and activation of p-NFKB. **(B)** In-vitro cell growth of MOLM-13 and RS4;11 overexpressing EV or IKBKB-EE upon LAMP5 downregulation. Data is from 3 technical replicates, representative of at least 3 experiments. **(C)** Western blot analysis showing the expression of the Germline MLL1 and MLL-AF9, C-term AF9, LAMP5 and actin after LAMP5 knockdown in MOLM13 and THP1 cell lines.



Supplemental Figure 6: (A)Representative images of THP-1 cells transduced with shNT/shIRF7/shLAMP5/shCombo(shIRF7/shLAMP5) after one week in methylcellulose. **(F)** Relative expression of *LAMP5* and *IRF7* after knockdown of LAMP-5, IRF7, or LAMP-5 and IRF7 together.



Supplemental Figure 7: Graphical Abstract. **Left panel:** ① The MLL-FP induces expression of LAMP5. ② LAMP5 gets internalized from the cell surface to the IFN signaling Endosome (IFN-SE), ③. ④ LAMP5 is quickly shuttled to the LAMP1+ pro-inflammatory signaling endosome (PI-SE), activating NF-κB signaling. ⑤ NF-κB activates pro-inflammatory signaling **Right panel:** Depletion of LAMP5 leads to blockage of transport and retention of TLR in the PI-SE, with activation of the IFN-SE and induction of Interferon related genes. Left panel depicts surface-LAMP5 can be targeted in MLL-r leukemias with immunotherapies.